Magnetic nanoparticles possess many characteristics that make them promising as drug carriers and for use in biomedical applications. They can be attracted or magnetically guided by strong magnetic fields, thus acting as drug carriers. They can also be used for hyperthermia applications, due to the heat they produce in an alternating magnetic field. The resulting temperature increase can be used to modify or inhibit specific cell activities locally, or even to release drugs in a precisely controlled, temperature-increase activated manner. Magnetic nanoparticles can also serve as contrast agents for diagnostic applications such as magnetic resonance imaging.
Introduction
Magnetic nanoparticles occur frequently in nature. They are found not only in the mineral world but also in living organisms. Well known examples are magnetotactic bacteria, which are believed to navigate the waters they live in, by using internal magnetic crystals aligned in chains that function as a compass. Higher forms of life, such as humans, also employ iron as an essential metal. In order to ensure a constant supply of iron, the body stores it within the well-defined protein shell ferritin as a 5 to 7 nm hydrous ferric oxide nanoparticle. 1, 2 The use of magnetic powders in medical applications was already conceptualized by ancient Greek and Roman scientists. 3 However, magnetic nanoparticles have only been used since the mid 1970s in the area of biological and medical sciences. 4 A wide range of in vivo as well as in vitro applications have been or are currently being developed. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These applications include magnetic drug delivery, magnetic fluid hyperthermia, magnetic cell separation and extraction when an external magnetic field is applied, and contrast enhancement for diagnostic imaging procedures, as the magnetic nanoparticles' own magnetic field influences their surrounding. From a practical point of view, magnetic nanoparticles are thus versatile tools that enhance yields for many in vitro processes such as cell purifications. In addition, in general, no invasive procedures are required when they are used for in vivo therapies.
Definitions
The development of nanoparticles for biomedical applications requires contributions from the basic to the medical sciences. Such interdisciplinary interactions can sometimes lead to communication problems. For example, the term magnetic nanoparticle has a different meaning for a physician and a biochemist, and might have no meaning at all for a physicist. For this reason, definitions satisfying all partners involved in the present research field are required. With the following simplified definitions, we attempt to provide a universal starting point.
Properties of magnetic materials
The magnetic properties of materials are mainly related to electrons, with all materials showing some kind of magnetic behavior. Materials can be classified according to their response to external magnetic solicitations. Magnetic susceptibility is defined by the initial slope of the magnetic curve, presenting the magnetization "M" (response) as a function of an applied magnetic field "H" (solicitation) (Fig. 1 ). The observed behavior of different materials can be explained in terms of their magnetic structure at the atomic level, and can be summarized as diamagnetism, paramagnetism, and ferromagnetism. Diamagnetic materials consist of atoms with no net magnetic moment. Nevertheless, they tend to oppose any external magnetic field change due to induced dipoles in the material. For this reason, they are characterized by a slight negative magnetic susceptibility. Paramagnetic materials are made of atoms showing a net magnetic moment. The random orientation of these moments is responsible for a slight positive magnetic susceptibility and no magnetization remains when the external magnetic field is switched off (see Fig. 1 ). Ferromagnetic materials react strongly to external magnetic fields, unlike dia-and para-magnetic materials. They can be viewed as paramagnetic materials with an organized domain structure (see Fig. 1 ). Within a domain, all atomic magnetic moments are parallel. When submitted to an external magnetic field, the different domains, initially in a random orientation, tend to align according to the Atomic magnetic moment structure (upper drawings) and corresponding magnetization curves (lower graphs). Paramagnetic materials show random atomic moment orientation which is responsible for their weak response to magnetic solicitations and no remanence. A typical ferro-or ferri-magnetic material shows a characteristic domain structure with associated hysteresis magnetization curve. Superparamagnetic materials present a thermally induced oscillating magnetic moment and a strong magnetic response to external magnetic fields (red curve). Their saturation magnetization is comparable to ferro or ferri-magnetic materials (black curve), but without remanence as in the case of paramagnetic materials (blue curve). For a given particle composition, all three behaviors might be encountered, depending on temperature or particle size (upper arrows).
external field. This alignment requires domain wall motions and results in hysteresis of the magnetization curve. After the external field is switched off, a remaining or remanent magnetization "M R " can be observed. Again, in order to achieve a random domain orientation, more energy must be provided by means of an external magnetic field applied in the opposite direction. A coercive field "H C " is defined as the value of the external field necessary to misalign the domains to a random state. More detailed information is available in the literature. [16] [17] [18] [19] [20] Magnetic materials can be composed of different atoms and ions with various magnetic moments. The most well known example is magnetite (Fe 3 O 4 ), which consists of Fe 2+ and Fe 3+ ions. The crystallographic structure of such materials determines whether or not antiferromagnetic or ferrimagnetic properties are present. For magnetic drug targeting, only ferro-and ferri-magnetic materials are of interest, as they react strongly to external magnetic fields due to their non-zero atomic or lattice unit magnetic moment and the domain structure. Temperature also plays a role in the magnitude of magnetic response, as high thermal energy can disturb the atomic moment orientation within the domains, leading to paramagnetic behavior. When ferro-or ferri-magnetic materials are divided, the obtained nanoparticles can become small enough to show single domain structure with a non-zero magnetic moment. Depending on the particle size, the thermal energy might be high enough to have the particles magnetic moment switch between energetically favorable (or easy) directions. These directions are defined by the particle structure, especially the crystallography, the shape and the surface. As a result of the moment oscillation, the net particle magnetization is zero and no remanent magnetization is observed, but the particles still strongly react to external magnetic solicitations (see Fig. 1 ). This behavior, called superparamagnetism, is generally encountered for particles that are a few nanometers in size. Superparamagnetism can be influenced by magnetic interparticle interactions, which lead to collective behavior of several particles acting as one bigger particle. The observation time is also important and must be longer than the particle relaxation time, necessary to switch from one to the other easy direction.
Nanoparticles
No single definition exists to describe a nanoparticle. Most of the time, an arbitrary size range is used ("nanometer sized", from 10 −9 to 10 −6 m). In view of the recent developments in nanotechnology, some people now use the drastic behavior changes arising below a critical size (such as the superparamagnetic state described earlier) to define nanoparticles. When reducing nanoparticle size, not only does the surface over volume ratio increase gradually, but a complete modification of the material properties may also occur. This is of primary importance in the biomedical field, where a change in size can lead to toxic effects. Many unanswered questions remain in this field and legal aspects related to nanoparticles are currently under discussion. 21 For use in biomedical applications, ferro-, ferri-or superparamagnetic particles must be coated to ensure colloidal stability, increased circulation time in the body, functional surfaces, and appropriate diagnostic properties. In this regard, the term "magnetic nanoparticle" not only refers to an inorganic core responsible for magnetic properties, but also to a composite structure with one or several cores coated or embedded in a matrix. Coatings are reviewed elsewhere in this book.
In addition to a compatible coating, magnetic nanoparticles used in clinical applications must form stable aqueous suspensions. Suspensions are complex dynamic systems. Their equilibrium is influenced by the forces present, including Van der Waals, electrostatic, steric, and magnetic forces, as well as by Brownian motion. On this account, it is crucial to realize that solvent modifications can drastically influence the behavior of the system. The term "ferrofluid" is correctly used only in the case of a colloidal stable suspension of single domain nanoparticles. 22 
Magnetic Nanoparticles
In general, a single particle type cannot be used for all applications. Instead, the composition, size and production route of synthesized magnetic nanoparticles is determined by the target application. Although superparamagnetic, ferro-and ferrimagnetic particles can all be used for magnetic drug carrier applications, superparamagnetic particles are favored for biomedical applications, due to the fact that they behave non-magnetically when they are not under the influence of an external magnetic field, thus preventing undesired magnetic agglomeration. To further assist in preventing agglomerations, to optimize bio-interactions with the host environment and to maximize biocompatibility, the choice of appropriate surface chemistries and functionalizations is also important. Many magnetic nanoparticles are available with different surface chemistries, and details about the properties of these chemistries are given elsewhere in this book.
The following subsections provide an overview of magnetic nanoparticles as drug carriers, classified according to magnetic composition. The final subsection deals with the general biocompatibility issues of magnetic nanoparticles.
Iron oxide based magnetic nanoparticles
In biomedical applications, the most commonly used magnetic nanoparticles are superparamagnetic magnetite (Fe 3 O 4 ) and maghemite (γ-Fe 2 O 3 ). This is due to their ease of synthesis using chemical or physical approaches, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] as well as their general bio-compatibility (and FDA approval). Massart's aqueous coprecipitation method, 34 which leads to particles easily dispersible in water, is the most cited method of magnetic nanoparticle preparation. The particle size can be tuned in the 3 to 30 nm size range 35 and the particles usually show an ellipsoidal shape.
The stoichiometry ranges from magnetite to maghemite, the two crystallographic structures being very similar. [35] [36] [37] [38] The size distribution is about 10 to 20% [see 
39-47
Iron oxide nanoparticles have been synthesized intensively during the past decades, but until recently, phase and size control have been problematic. A newly developed two-step approach has allowed for much better control over the particle 48 and (b) Decomposition at high temperature of organic precursors. 49 Despite its much improved size and shape distribution, the second particle type suffers from two major drawbacks for biomedical applications: Biocompatibility and the ease of dispersion in water based solvents.
structure. In this approach, metal particles are first obtained and then oxidized in a controlled way. 50 Size distributions of better than 5% can be achieved in the 4 to 16 nm range, as shown by Alivisatos et al. 51 and Hyeon et al. 49 [see Fig. 2 (b)]. These particles are, however, often not appropriate for biomedical applications as they do not disperse easily in water. 52 Many other magnetite and maghemite nanoparticle synthesis approaches can be found in the literature, but none are significantly different from the ones presented above. Slightly modified nanoparticles can also be obtained by partly replacing the iron in the magnetite or maghemite structure with cobalt or nickel. This in turn changes the magnetic properties of the particles. More details are given in a recent and extensive review by Tartaj et al. 53 
Cobalt based magnetic nanoparticles
From a magnetic point of view, particles showing a stronger reaction to magnetic fields are desirable. Cobalt achieves this aim, but its toxicity is a major drawback. One way of preventing or minimizing this toxicity caused by cobalt ion leakage is the inorganic encapsulation of cobalt with, for example, silica.
Iron based magnetic particles
Pure iron nanoparticles can be synthesized, but their sensitivity to oxidation is a major drawback for biomedical applications. Thus, a coating, as described for cobalt particles, should be used. Iron has also been coated or alloyed with platinum, cobalt and carbon.
Encapsulated magnetic nanoparticles
Depending on the application, magnetic nanoparticles may be combined into larger conglomerates to increase the overall magnetic moment (see Fig. 3 ). Great care should be paid to interparticle magnetic interactions. The superparamagnetic behavior of a system might, for example, be lost due to such interactions. Also, the magnetic core concentration must be kept constant among the magnetic conglomerates to yield homogeneous magnetic moments, and thus a consistent response to an applied magnetic field.
Either a single or a two-step approach can be used to synthesize magnetic particles. 54 In the one-step approach, a "linker" is present while synthesizing the magnetic nanoparticles. In the two-step approach, the linker is added subsequently. The linker can be organic or inorganic and is chosen for its chemical and biocompatible characteristics. For biomedical applications, dextran, starch, polyethylene glycol (PEG), polyvinyl alcohol (PVA), silica and gold are among the most common compounds. 
Biocompatibility issues of magnetic nanoparticles
One of the first papers to discuss the biocompatibility issues of magnetic particles was published in the early 1970's by Nakamura et al. 55 The authors prepared fine carbonyl-iron particles and infused them into different animal species in vivo. They concluded that to achieve optimal results, the magnetic particles should be coated with a biocompatible material and be as round as possible.
(a) (b) maghemite particle silica Further research showed that pure magnetic metal particles, such as iron, cobalt and nickel particles, should not be used directly in vivo because they oxidize easily and release +2 or +3 charged metal ions that can exert unwanted as well as toxic effects. Iron ions, for example, are problematic in that they produce and catalyze oxygen radical formation. 56 Cobalt and nickel ions have been found to induce adverse tissue reactions, and to promote infection and metal sensitivity. 57 In contrast to pure magnetic particles, iron oxides and superparamagnetic iron oxide nanoparticles (SPION) coated and stabilized with hydrophilic polymers have been found to be quite thermodynamically stable under physiological conditions, not exerting obvious toxic effects. In fact, they are similar in size and core composition to the natural non-toxic magnetic nanoparticles found in magnetotactic bacteria 58 and in human tissue. 59 Pharmacokinetic studies of small magnetite nanoparticles destined for magnet resonance imaging 60, 61 have shown that the magnetite nanoparticles are taken up by the cells of the reticuloendothelial system (RES) and are transported intracellularly to lysosomes, where they slowly oxidize at low pH and are then recycled by the body. 62 Within 20-40 days, up to 60% of the iron is recovered in the red blood cells, as determined using radiolabeled 59 Fe.
Recent discussions have centered on the fate and toxic effects of (magnetic) nanoparticles in humans after inhalation. Rodent models have shown the potential problematic effects of such particles to include the induction of asthma, inflammation, and potentially even cancer. 63 Some of these effects might be due to the fact that particles smaller than 100 nm are not exhaled, but are almost completely retained in the alveoli. 64 For this reason, acute effects can rapidly turn into chronic effects.
Another possible cause for concern is the report that small particles have been found behind the blood brain barrier 65 (see also Chap. 24). Further research needs to clarify if these particles directly crossed the blood brain barrier or via the nose. Care must be taken to relate the effects seen in animal models to the human situation, especially since effects seen in rodents do not seem to develop in humans. 63 Clarification of the short and long term risks of nanoparticle use is the aim of several programs being initiated in 2005 by the European, American and Canadian governments.
Application of Magnetic Nanoparticles as Drug Carriers
The following section presents an overview of the use of magnetic nanoparticles sized 1 µm or less for the delivery of drugs. Magnetic microspheres of larger than 1 µm size are also mentioned in a few places, but for a recent and thorough review, as well as for the history of magnetic drug delivery, the reader is advised to consult a more extensive treaty on this matter such as the recent volume of the MML series. 66 In this section, magnetic nanoparticles will be grouped according to their mechanism of action including magnetic hyperthermia; the delivery of magnetic nanoparticles that (slowly) release drugs (tumor treatment, thrombolysis, delivery of antiinfective, antiarthritic, antifungal, and antiscar agents, and local anesthesia or neuroblocking agents) or act without drug release (radiotherapy or embolization); and the improved delivery of peptides (gene transfer). Results from in vitro, in vivo and clinical work will be discussed.
Magnetic hyperthermia
Magnetic nanoparticles in an alternating current (AC) magnetic field produce heat by Néel and Brownian relaxation. 67 (2), rectal, and prostate (2) carcinoma, as well as for a chondrosarcoma, rhabdomyosarcoma, and liver metastasis. During the 1-hour sessions, after local injection of the magnetic particles, the tumor temperature increased to [43] [44] [45] [46] [47] [48] [49] [50] • C under the influence of a magnetic field of 3 to 9.5 kA/m and a frequency of 100 kHz. While no additional nanoparticle injections were necessary, the hyperthermia treatment was repeated from 2-11 times. The magnetic fluid hyperthermia was well tolerated. Two patients showed complete remission 9 and 14 months after treatment, while the other six patients showed local control with no recurrent growth of the tumors. These results are very promising. Another group in Germany led by Hilger is working on circumventing the drawback of having to directly inject the particles into a tumor, by using antibodybound magnetic nanoparticles which are able to target breast cancer, followed by magnetic field hyperthermia. 79, 80 Although their particles are taken up extensively by tumor cells and show a specific heating power of up to 170 W/g, 81 there is still more work needed to increase the number of particles in the tumor and to reach a homogeneous tumor distribution. 82 Magnetic hyperthermia is also possible with large microspheres that contain magnetic nanoparticles. 83, 84 As an example, Moroz et al. incorporated 100 nm maghemite particles into 32 µm biocompatible plastic particles and then embolized the arterial blood supply of liver tumors with them. In an animal study with 10 rabbits, the VX2 tumor volumes decreased significantly within 2 weeks.
85-87
The development of maghemite nanoparticles with very high AC losses is ongoing. Hergt et al. are in the process of characterizing the largest, but still superparamagnetic particles, 88 optimizing the coatings such as carboxydextran or polyethylene glycol, 89 and investigating the exact mechanism of heat production in an AC magnetic field. 88 Magnetic hyperthermia is an exciting cancer treatment possibility and is profiting from ongoing research into its mechanism of action and from improved magnetic materials. The proof of principle has advanced to the clinical stage with the construction and clinical testing of Jordan's magnetic field therapy system. 77 The targeted (cancer) cell uptake of sufficient amounts of magnetic nanoparticles from a patient's blood supply could make magnetic hyperthermia the method of choice for many different kinds of tumors.
Magnetic chemotherapy
Magnetic drug delivery is able to concentrate drugs in a tumor if the tumor is accessible through the arterial system and has a good supply of blood. Magnetic drug delivery thus promises to deliver highly effective anticancer drugs with fewer side effects, and with shorter and less toxic treatments. Most drug release from magnetic particles occurs passively, by desorption from and diffusion out of the particle matrix. The main driving forces are pH, osmolarity and concentration differences between particles and the blood/tissue. Widder and Senyei were the first to successfully illustrate this concept with the chemotherapeutic drug doxorubicin encapsulated into albumin-coated magnetite particles sized around 1-2 µm. 90 Targeting a distinct area of a rat's tail, they were able to deliver 200 times more of the drug than intravenous application of the same amount of free drug could achieve. 91 Taking it a step further, they treated Yoshida rats with sarcomas in their tails and attained complete remission in 77% of the rats.
92,93
The magnetic albumin microspheres were never tested clinically, likely because the magnetophoretic mobility (overall magnetic responsiveness to a magnetic field) was considered too low for deeper applications. This changed with the introduction of iron-carbon particles originally developed in Russia 94 and then brought to clinical trial by the company FeRx. FeRx's irregularly-shaped carbon-coated iron particles, of 0.5 to 5 µm in diameter and with a very high magnetic susceptibility, were loaded with doxorubicin and showed promising results and very low therapy-related toxicity in the treatment of inoperable liver cancer. 95, 96 Unfortunately, FeRx ceased to exist in 2004 when a preliminary analysis of their ongoing clinical trial failed to convince investors of the method's superiority over other treatment methods. Not only doxorubicin, but also many other chemotherapeutic drugs can be and have been adsorbed to magnetic nanoparticles made from many different matrix materials. Examples of chemotherapeutic magnetic nanoparticles tested in vivo include polyalkylcyanoacrylate nanoparticles of 220 nm diameter filled with (adsorbed) dactinomycin, 97 chitosan nanoparticles of 530 nm diameter loaded with oxantrazole, 98 solid lipid nanoparticles of 450-570 nm diameter loaded with methotrexate, 99 and ferro carbon of 100 nm diameter loaded with carminomycine. 94 Each of these nanoparticles has been tested in animal experiments with positive results. Specifically, after intravenous injection, the drug concentration tripled in the target organ when a magnet was placed above it, compared with a control without an applied magnet. It seems that the intravenous injection of magnetic nanoparticles, even very close to the target region, is not optimal. This was well documented in a clinical cancer therapy trial performed by Lübbe et al. in 14 patients. 100,101 They used magnetic nanoparticles of 100 nm in diameter loaded with 4'-epidoxorubicin for the treatment of advanced solid cancer. The phase I study clearly showed accumulation of magnetic nanoparticles in the target area without toxic effects. MRI measurements, however, indicated that more than 50% of the magnetic nanoparticles were deposited in the liver. This was likely due to the particles' low magnetic susceptibility and small size, which limited their ability to be held at the target organ. Intraarterial injection into the blood supply that leads to the target region might be much more effective for magnetic drug targeting for this reason.
The above examples of magnetic drug targeting with magnetic nanospheres are only a subset of all the magnetic drug delivery attempts. A more complete compilation is given by Hafeli. 66 In addition, all the important factors in magnetically controlled targeted chemotherapy are extensively described in a review by Gupta and Hung. 
Other magnetic treatment approaches
Under the influence of a magnetic field, magnetic particles align in chains and eventually agglomerate. Depending on particle size and shape, this can lead to embolization (clogging) of the blood vessels and especially of the small capillaries of 7 to 10 µm in diameter. This accumulation of particles can be used on its own to starve the target tissue of oxygen, produce hypoxia and induce necrosis. The magnetic particles used for this approach are generally larger, such as the "iron sponge" of 10-30 µm used by Sako et al., 103, 104 but can also consist of nanoparticles in a more lipophilic solvent such as the ferrosilicone employed by Turner et al. 70 Turner added a catalyst to their ferrosilicone suspension, which resulted in vulcanization of the viscous slurry 14 min after injection into 7 patients with diverse solid tumors. 70 Magnetic particles can also be used for tumor treatment without releasing any drugs. For this purpose, magnetic particles can incorporate radioisotopes either in the matrix or bound to their surface, and then deliver tumor cell-toxic radiation doses wherever they accumulate. 105 External magnetic fields or internal magnetizable wires 106, 107 can be used to accumulate radioactive magnetic particles and hold them at the target site. The particles irradiate the area within the specific treatment range of the isotope. Initial experiments in mice showed that intraperitoneally injected radioactive poly(lactic acid) based magnetic microspheres (10-20 µm in diameter) could be concentrated near a subcutaneous tumor in the belly area above which a small magnet had been attached. 108 The dose-dependent irradiation from the radioisotopes. 109, 110 Targeting studies to distinct liver regions in swine by our group (unpublished results) showed that more than 90% of the injected radioactive magnetic particles were accumulated underneath a strong NdFeB-magnet. The radioactive particles stayed in the target region for at least 3 days, even after the removal of the magnet.
Magnetic nanoparticles of much smaller diameters are being used clinically for diagnostic purposes, mainly as contrast agents. 111 The accumulation of these magnetic particles is, however, based on non-specific properties such as the tissuespecific pore size (fenestration) or enhanced permeability and retention effect (EPR) seen in tumor tissues, but not on magnetic targeting. Recent examples of nonspecific targeting are the internalization into cells of the positively charged at peptide bound to therapeutic agents, such as radioactively complexed 99m Tc and 188 Re, 112 and superparamagnetic iron oxides known as tat-CLIO (tat-cross linked iron oxides). 113 Magnetic drug delivery is also able to deliver other types of drugs such as highly potent antiinfective, blood clot-dissolving, anti-inflammatory, anti-arthritic, photodynamic therapy and paralysis-inducing drugs, among many others. 66 A good example of these applications was reported in 1988. 114 In this study, Torchilin et al.
surgically induced a thrombus in both carotid arteries of a dog, fixed a permanent magnet near one of them, and 1 hr later, intravenously injected 1 µm-sized dextran microspheres with covalently bound streptokinase. The side without the magnet completely occluded within 4 hrs, while the magnet side returned to initial blood flow conditions after about 30 min and appeared completely open at histological examination. Torchilin noted that these results were achieved using doses 10 times lower than those used when streptokinase is directly injected. Similar results were obtained in the same year by another group using 30-60 nm PEGylated magnetite particles containing urokinase. 115 In both cases, the thrombolytic activity remained at background levels outside the targeted region.
Magnetic gene transfer
The newest application of magnetic nanoparticles is for targeted and enhanced gene delivery in potential applications such as wound repair 116 and the treatment of cancer, 117, 118 eye disease, 119 and cystic fibrosis. 120 Magnetically enhanced gene transfer may be able to overcome the current lack of selectivity of the existing vectors and low efficiency of gene transfer. The mechanisms by which magnetic nanoparticles can improve on transfection rates are by magnetically forced contact 121, 122 and by increasing the plasmid concentration magnetically. 123 Magnetofection was first described in a Japanese patent by Harata et al. who used magnetic liposomes to transfect cells. 124 Bergemann et al. described the first experiments of transfecting cytokine-induced killer cells (CIK-cells) with plasmid DNA carrying distinct interleukin genes. However, their magnetic nanoparticles were only used as plasmid carriers, not as the driving force, which was provided by electroporation. 12 Using a magnet as the driving force was then described a couple of years later by Plank et al. 122, 125 For successful in vitro and in vivo transfections, only very small amounts of plasmid were necessary, and the transfection occurred in a matter of just a couple of minutes. This speedy and efficient transfection at low vector doses is the main advantage of magnetofection. Furthermore, remotely controlled vector targeting in vivo seems possible.
Conclusions
The technological advancements in the material and engineering sciences, and especially in the nanotechnology revolution, with its increasing molecular approach to the synthesis, derivatization, combination, self-assembly, and manipulation of materials, will guide improvements in all aspects of magnetic nano-and microparticles. These advancements include the synthesis of higher magnetic nanophases; the increasing availability of stronger magnets and engineered magnetic fields; the ability to prepare more uniform particles; and the rendering of these particles biocompatible and ultimately biodegradable without toxicity. For real therapeutic breakthrough, however, a few challenges in the field of magnetic drug delivery still need to be addressed. One of the challenges is the difficulty involved in generating the focused field profiles needed to target magnetic nanoparticles deep within the body, due to the speed with which the magnetic fields drop off as their distance from the source increases (intensity = 1/r 3 ). Another challenge centers on attaining homogeneous particle distributions given that blood flow in the target region can vary from very fast (100-200 cm/s) to very slow (0.05 cm/s). A final challenge is the optimization of magnetic nanoparticles in terms of magnetization and size uniformity. All these problematic areas are currently being addressed by multidisciplinary groups worldwide, as evident from a special issue of the J Magn Magn Mater 293:1-736, containing 107 original peer-reviewed papers that were submitted at the 5th International Conference on the Scientific and Clinical Applications of Magnetic Carriers in 2004 (www.magneticmicrosphere.com). The potential of magnetic drug delivery is great. In addition to their magnetic responsiveness, magnetic nanoparticles carry an innate signal that can be used for magnetic resonance imaging. 126 Furthermore, other imaging modalities such as radioisotope or fluorescence imaging can be used after derivatizing the particle surface. There is no limitation to the kind of drugs that can be encapsulated or bound to magnetic nanoparticles. 66 Also, current pharmaceutical techniques allow for the development of drug release profiles for a large group of drugs and diseases. Magnetic targeting devices such as the recently FDA approved Niobe system (Stereotaxis Inc., St. Louis, Missouri, U.S.A.) 127 improve on the precise manipulation of magnetic forces. Anatomical and physiological conditions in a patient are, however, complicated, and successful therapies will have to be specifically adapted to each disease and ideally applied under imaging control.
The treatment of cancer is an especially good target for magnetic drug delivery. However, any disease that could benefit from precise control over the delivery of highly effective, but potentially toxic substances would also be a good candidate. For example, antiangionic drugs could be delivered to the back of the eye to prevent blindness in patients with age-related macular degeneration. Attempts to develop such a drug delivery system are ongoing. 128, 129 
